Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 4, 2012, Pages 557-564

  von Bahr, Lena ^a   Sundberg, Berit ^a   Lönnies, Lena ^a   Sander, Birgitta ^a   Karbach, Holger ^a   Hägglund, Hans ^a   Ljungman, Per ^a   Gustafsson, Britt ^a   Karlsson, Helen ^a   Le Blanc, Katarina ^a   Ringdén, Olle ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Graft versus host disease; Hematopoietic stem cell transplantation; Mesenchymal stem cells

Indexed keywords

CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; HLA G ANTIGEN; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VALGANCICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; CAUSE OF DEATH; CHILD; CHILDHOOD MORTALITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTITIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS INFECTION; ESCHERICHIA COLI INFECTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFECTION COMPLICATION; LEUKEMIA; LEUKEMIA RELAPSE; LONG TERM SURVIVAL; MALE; MESENCHYMAL STROMA CELL; MIXED LYMPHOCYTE CULTURE; MYCOSIS; OUTCOME ASSESSMENT; PREDICTION; PRESCHOOL CHILD; PUVA; SCHOOL CHILD; STAPHYLOCOCCUS INFECTION; SURVIVAL RATE; THERAPY RESISTANCE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CYSTITIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEUKEMIA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; VIRAL LOAD;

EID: 84858080480     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.023     Document Type: Article

References (25)

1. Friedenstein A.J., Petrakova K.V., Kurolesova A.I., Frolova G.P. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968, 6:230-247.
2. Haynesworth S.E., Goshima J., Goldberg V.M., Caplan A.I. Characterization of cells with osteogenic potential from human marrow. Bone 1992, 13:81-88.
3. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
4. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.
5. Karlsson H., Samarasinghe S., Ball L.M., Sundberg B., Lankester A.C., Dazzi F., et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008, 112:532-541.
6. Ringdén O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lönnies L., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 27(81):1390-1397.
7. Ringdén O., Uzunel M., Sundberg B., Lönnies L., Nava S., Gustafsson J., et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 2007, 27:2271-2276.
8. Ning H., Yang F., Jiang M., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008, 22:593-599.
9. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of severe refractory acute graft-versus-host disease. Lancet 2008, 371:1579-1586.
10. Mattsson J., Uzunel M., Remberger M., Ringdén O. T-cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2001, 71:433-439.
11. Ljungman P., Brand R., Einsele H., et al. CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003, 102:4255-4260.
12. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 15(34):1094-1097.
13. Emery V.C., Sabin C.A., Cope A.V., Gor D., Hassan-Walker A.F., Griffiths P.D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355:2032-2036.
14. Ferrara J.L. Advances in the clinical management of GVHD. Best Pract Res Clin Haematol 2008, 21:677-682.
15. Le Blanc K., Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:321-334.
16. Paulin T., Ringdén O., Nilsson B. Immunological recovery after bone marrow transplantation: role of age, graft-versus-host disease, prednisolone treatment and infections. Bone Marrow Transplant 1987, 1:317-328.
17. Chapel A., Bertho J.M., Bensidhoum M., et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003, 5:1028-1038.
18. Gao J., Dennis J.E., Muzic R.F., et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001, 169:12-20.
19. Rizzo R., Campioni D., Lanza F., et al. Cotransplantation of mesenchymal cells and a higher relapse rate: a role for HLA-G molecules?. Leukemia 2008, 22:2273.
20. Nasef A., Mathieu N., Chapel A., et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007, 84:231-237.
21. Lila N., Carpentier A., Amrein C., et al. Implication of HLA-G molecule in heart-graft acceptance. Lancet 2000, 355:2138.
22. Creput C., Durrbach A., Charpentier B., et al. HLA-G immunoregulatory molecule involved in allograft acceptance. Nephrologie 2003, 24:451.
23. Ringdén O, Boström L, Paulin T. On herpes virus immunity, graft-versus-host disease, pneumonitis and relapse. Bone Marrow Transplant. Current Controversies. UCLA Symposia, 1989, Vol. 91, pp. 573-584. New York: Alan R. Liss Inc.
24. Grundy J.E., Shanley J.D., Shearer G.M. Augmentation of graft-versus-host reaction by cytomegalovirus infection resulting in interstitial pneumonitis. Transplantation 1985, 39:548-553.
25. Samuelsson H., Ringdén O., Lonnies L., et al. Optimising in vitro conditions for immunomodulation and expansion of mesenchymal stem cells. Cytotherapy 2009, 11:129-136.